Sinopharm Zhonglian has a long history and is an old-fashioned enterprise in Chinese medicine industry. It is jointly established by 192 Chinese medicine shops with a history of more than 400 years, which are well-known in China, represented by Ye Kaitai, Darentang, Liu Youtang, Jin Tongren, Jiuzhitang and Chen Taiyi. 1952, Wuhan Zhonglian Pharmaceutical Factory was established at the initiative of the former Wuhan Traditional Chinese Medicine Pieces Industry Association. 65438 was restructured into 0997, and a group company was established in 2002. 20 1 1 Reorganized at the end of the year and entered China Pharmaceutical Group, the largest health industry platform in China. After more than 60 years of development, the company has formed a variety of industrial structures, including the production and sales of Chinese patent medicines, chemical preparations, pharmaceutical business operations and so on. , has become a professional medical and health enterprise integrating scientific research, production, circulation and foreign trade. It is a national high-tech enterprise and the first batch of time-honored enterprises awarded by Hubei Province.
The company focuses on the production and sales of classic Chinese medicine. There are 32 registered products1product, 7 varieties1product listed in the national essential drugs list, 8 national exclusive varieties1product, and 63 national medical insurance varieties1product. Among them, Wan Jian is a strategic variety with a history of more than 2,000 years, and it is a classic ancient prescription of Zhang Zhongjing in Han Dynasty, which specializes in treating hypochondriac diseases. The company's key products involve liver drugs, respiratory drugs, gynecological drugs, cardiovascular and cerebrovascular drugs and other special fields. And formed a series of liver drugs represented by Biejiajian Pill, respiratory drugs represented by Jinye Baidu Granule, Biyan Tablet and Li Qiang Ganmao Tablet, cardiovascular and cerebrovascular drugs represented by Maijun 'an Tablet and Xinnaoqing Soft Capsule, and gynecological drugs represented by Jiawei Biochemical Granule.
The company pays attention to the systematic and in-depth development of Chinese medicine classics. Relying on the R&D platform of China Pharmaceutical Industry Research Institute under Sinopharm Group, we have carried out extensive cooperation and exchanges at home and abroad, constantly explored the mechanism of classical ancient prescriptions, researched new technologies, ensured the efficacy of products, and owned a number of independent intellectual property rights, which laid a solid foundation for the company's sustainable development.
"Zhonglian" is an old brand in the field of traditional Chinese medicine in China, which enjoys high popularity and reputation in Hubei Province. The company's marketing network covers many provinces, autonomous regions and municipalities directly under the central government, and its terminal sales outlets cover the whole country. The main products are exported to Japan, Malaysia, Indonesia, the United States and other countries and regions. The company not only sells products, but also devotes itself to passing on the philosophy (culture) of traditional Chinese medicine and the core values of products to doctors and patients, making Zhonglian a medical enterprise respected by doctors and patients and making contributions to the development of traditional Chinese medicine in China.
The "Zhonglian Traditional Chinese Medicine Industrial Park" built by the company in Optics Valley Bio-city, East Lake High-tech Development Zone, according to modern Chinese medicine production standards, has been completed. In the future, based on this, the company will take "excavating, inheriting and innovating China traditional Chinese medicine and providing classic Chinese medicine for the family" as its own responsibility, inherit and carry forward China traditional Chinese medicine, and strive to become a first-class modern Chinese medicine enterprise in China. At the end of the 13th Five-Year Plan, the operating income exceeded 10 billion yuan, the profit exceeded 1 0 billion yuan, and the employee income reached the forefront of the same industry.